Business, energy, technology, markets and global industry news from Business News Today

Agios Pharmaceuticals

Features & Analysis

Gene editing can nearly eliminate sickle cell crises. A daily pill may still reach far more patients

Gene therapy can transform sickle cell disease, but etavopivat shows why scalable oral treatments may ultimately reach a much larger patient population.

Read More
Pharma & Biotech

Can Avanzanite accelerate NHS access to rare disease medicines in the UK?

Avanzanite appoints Sarah O'Connell to expand UK rare disease operations. The move strengthens its European commercialisation and patient access strategy.

Read More
Pharma & Biotech

Agios Pharmaceuticals stops tebapivat sickle cell development after mixed Phase 2 results

Agios Pharmaceuticals, Inc. has decided not to advance tebapivat in sickle cell disease after a randomized Phase 2 trial involving 59 participants failed to establish the differentiated clinical profile required for further investment. The Nasdaq-listed rare-disease drug developer said the once-daily pyruvate kinase activator improved haemoglobin and markers of haemolysis, but the response pattern did

Read More
Pharma & Biotech

Why mitapivat’s Phase 3 data could change the sickle cell disease treatment debate

Find out how Agios’ mitapivat Phase 3 data could shape the next treatment debate in sickle cell disease care.

Read More
Pharma & Biotech

Could Agios and Avanzanite turn PYRUKYND into Europe’s next rare blood disease launch test?

PYRUKYND has EU approval in thalassaemia. Now Agios and Avanzanite face Europe’s harder test: access, uptake and reimbursement.

Read More